Bangladesh · Delayed Price · Currency is BDT DSE:SQURPHARMA Statistics
Total Valuation
DSE:SQURPHARMA has a market cap or net worth of BDT 188.37 billion. The enterprise value is 129.31 billion.
| Market Cap | 188.37B |
| Enterprise Value | 129.31B |
Important Dates
The last earnings date was Thursday, October 30, 2025.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Nov 17, 2025 |
Share Statistics
DSE:SQURPHARMA has 886.45 million shares outstanding.
| Current Share Class | 886.45M |
| Shares Outstanding | 886.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 35.97% |
| Owned by Institutions (%) | 4.79% |
| Float | 567.55M |
Valuation Ratios
The trailing PE ratio is 8.01.
| PE Ratio | 8.01 |
| Forward PE | n/a |
| PS Ratio | 2.48 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 22.99 |
| P/OCF Ratio | 13.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.33, with an EV/FCF ratio of 15.78.
| EV / Earnings | 5.50 |
| EV / Sales | 1.70 |
| EV / EBITDA | 5.33 |
| EV / EBIT | 5.87 |
| EV / FCF | 15.78 |
Financial Position
The company has a current ratio of 12.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.12 |
| Quick Ratio | 9.53 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.12 |
| Interest Coverage | 74.65 |
Financial Efficiency
Return on equity (ROE) is 18.33% and return on invested capital (ROIC) is 8.97%.
| Return on Equity (ROE) | 18.33% |
| Return on Assets (ROA) | 8.61% |
| Return on Invested Capital (ROIC) | 8.97% |
| Return on Capital Employed (ROCE) | 13.72% |
| Revenue Per Employee | 6.09M |
| Profits Per Employee | 1.89M |
| Employee Count | 12,453 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.11 |
Taxes
In the past 12 months, DSE:SQURPHARMA has paid 4.35 billion in taxes.
| Income Tax | 4.35B |
| Effective Tax Rate | 15.61% |
Stock Price Statistics
The stock price has decreased by -4.19% in the last 52 weeks. The beta is 0.10, so DSE:SQURPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -4.19% |
| 50-Day Moving Average | 216.66 |
| 200-Day Moving Average | 215.60 |
| Relative Strength Index (RSI) | 42.20 |
| Average Volume (20 Days) | 414,775 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:SQURPHARMA had revenue of BDT 75.86 billion and earned 23.50 billion in profits. Earnings per share was 26.51.
| Revenue | 75.86B |
| Gross Profit | 34.01B |
| Operating Income | 18.59B |
| Pretax Income | 27.86B |
| Net Income | 23.50B |
| EBITDA | 20.80B |
| EBIT | 18.59B |
| Earnings Per Share (EPS) | 26.51 |
Balance Sheet
The company has 50.52 billion in cash and 977.79 million in debt, giving a net cash position of 59.07 billion or 66.64 per share.
| Cash & Cash Equivalents | 50.52B |
| Total Debt | 977.79M |
| Net Cash | 59.07B |
| Net Cash Per Share | 66.64 |
| Equity (Book Value) | 134.69B |
| Book Value Per Share | 151.94 |
| Working Capital | 68.11B |
Cash Flow
In the last 12 months, operating cash flow was 13.72 billion and capital expenditures -5.53 billion, giving a free cash flow of 8.19 billion.
| Operating Cash Flow | 13.72B |
| Capital Expenditures | -5.53B |
| Free Cash Flow | 8.19B |
| FCF Per Share | 9.24 |
Margins
Gross margin is 44.84%, with operating and profit margins of 24.51% and 30.98%.
| Gross Margin | 44.84% |
| Operating Margin | 24.51% |
| Pretax Margin | 36.72% |
| Profit Margin | 30.98% |
| EBITDA Margin | 27.42% |
| EBIT Margin | 24.51% |
| FCF Margin | 10.80% |
Dividends & Yields
This stock pays an annual dividend of 12.00, which amounts to a dividend yield of 5.65%.
| Dividend Per Share | 12.00 |
| Dividend Yield | 5.65% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 41.12% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.65% |
| Earnings Yield | 12.48% |
| FCF Yield | 4.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 23, 2020 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
DSE:SQURPHARMA has an Altman Z-Score of 19.4 and a Piotroski F-Score of 5.
| Altman Z-Score | 19.4 |
| Piotroski F-Score | 5 |